Novavax (XSWX:NVAX) Current Deferred Revenue: CHF69.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NVAX Novavax Inc XSWX:NVAX
46 GF Score
Price CHF7.24
GF Value CHF2.58
! 6 Warning Signs
View Full Analysis

What is Novavax Current Deferred Revenue?

Novavax XSWX:NVAX +9.21% 46 Current Deferred Revenue is CHF69.2 Mil as of Jun. 2026. GuruFocus rates XSWX:NVAX with a GF Score™ of 46/100 and a GF Value™ of CHF2.58. The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Novavax's current deferred revenue for the quarter that ended in Jun. 2026 was CHF69.2 Mil.

Novavax Current Deferred Revenue Related Terms

Novavax Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Novavax's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Current Deferred Revenue Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,310.53 344.82 208.69 601.89 111.61

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.51 82.99 111.61 69.89 69.20
XSWX:NVAX
46GF Score
Novavax Inc XSWX:NVAX
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of CHF69.2 Mil mean?
Novavax (XSWX:NVAX) has a Current Deferred Revenue of CHF69.2 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Novavax and its competitors.
Is Novavax's Current Deferred Revenue too high?
Novavax's current Current Deferred Revenue is CHF69.2 Mil. Overall, Novavax has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Current Deferred Revenue compare to JBIO and AVLN?
Novavax's Current Deferred Revenue of CHF69.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Novavax and its competitors. Novavax's current Current Deferred Revenue is CHF69.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Current Deferred Revenue of CHF69.2 Mil. The stock's GF Value™ is CHF2.58, compared to a current price of CHF7.24 — trading 180.7% above its estimated fair value. The current Current Deferred Revenue is CHF69.2 Mil. Novavax's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Current Deferred Revenue is CHF69.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.

Key valuation signals for XSWX:NVAX:

  • Current Deferred Revenue: CHF69.2 Mil
  • GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for XSWX:NVAX

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.24
Price
CHF2.58
GF Value